JPRN-jRCT1031210111招募中4 期
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults - Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults
FUKUSHIMA SHINJI0 个研究点目标入组 20 人开始时间: 2021年5月25日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 60age old（—）
- 性别
- All
入选标准
- •1) Japanese healthy adults who need MR and yellow fever vaccines
- •2) 20 years old and over and under 60 years old
- •3) No history of yellow fever
- •4) No history of immunization of yellow fever vaccine
排除标准
- •1) Manifest fever (37.5 or more temperature)
- •2) Suffering from severe acute illness
- •3) History of anaphylaxis
- •4) Immunodeficiency
- •5) HIV infection
- •6) Immunosuppressive and Immunomodulatory Therapies
- •7) Neurological disorder
- •8) Thymus Disorder
- •9) History of hypersensitivity to MR and yellow fever vaccine
- •10) Other chronic medical conditions
- •11) Pregnancy
- •12) Brestfeeding
- •13) Other inappropriate condition for vaccination
研究者
相似试验
已完成
4 期
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adultsYellow fever, Measles and RubellaJPRN-UMIN000042738Tokyo Medical University Hospital Travellers' Medical Center14
进行中（未招募）
1 期
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.EUCTR2022-004118-12-ATMedical University of Vienna256
尚未招募
Unknown
Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in MozambiquePoliovirusPACTR202404654347323World Health Organization888
进行中（未招募）
不适用
An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children primed with a five component acellular pertussis vaccine at 3, 5 and 12 months of age, and a booster dose at 5½ years of age. - Tdap Booster studyEUCTR2008-008195-13-SESwedish Institute for Infectious Disease Control (SMI)
已完成
不适用
Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinomaRenal cell carcinomaJPRN-UMIN000014703The University of Tokyo Hospital15